Eli Lilly at TD Cowen Conference: Orforglipron Launch Strategy
#Eli Lilly #orforglipron #TD Cowen Conference #obesity treatment #launch strategy
📌 Key Takeaways
- Launch strategy for orforglipron was outlined
- Focus on market expansion for the oral obesity treatment
- Challenges include pricing pressures and portfolio concentration
📖 Full Retelling
On Monday, March 2, 2026, Eli Lilly (NYSE:LLY) executives presented at the TD Cowen 46th Annual Health Care Conference, detailing the company's launch strategy for its oral obesity treatment, orforglipron. The presentation emphasized plans to expand the market while addressing challenges such as pricing pressures and portfolio concentration.
🏷️ Themes
Pharmaceutical product launch, Market strategy, Obesity treatment innovation
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
On Monday, 02 March 2026, Eli Lilly (NYSE:LLY) presented at the TD Cowen 46th Annual Health Care Conference, outlining its strategic plans for the upcoming launch of orforglipron, an oral obesity treatment. The company highlighted both the potential market expansion and the challenges posed by pricing pressures and portfolio concentration.
Read full article at source